Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Approves Supplement for XTAMPZA ER by Collegium Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Collegium Pharma3 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/26/2026, 12:31:52 PM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of the supplemental application for XTAMPZA ER is significant as it strengthens Collegium Pharma's competitive position in the opioid pain management market. This development necessitates a strategic review by other companies in the sector to evaluate potential impacts on market share and differentiation strategies. Regulatory context from FDA (FDA AP — XTAMPZA ER (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and consider strategies for differentiation in the opioid space. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 2 competitive items passed relevance filtering for Collegium Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance Collegium Pharma's position in the pain management market, particularly in the opioid segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — XTAMPZA ER (SUPPL) (FDA). Entity match (xtampza er). This approval indicates a positive regulatory environment for opioid formulations, which may influence future submissions and approvals in this therapeutic area.

Key Risks

Elevated medium regulatory exposure for Collegium Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Collegium Pharma, potentially affecting revenue dynamics in the opioid segment as competitors may need to adjust their strategies.
Portfolio teams should assess the impact of this approval on market share and consider strategies for differentiation in the opioid space.

What Would Change This Assessment

This becomes more urgent if Monitor for any upcoming marketing strategies or additional indications for XTAMPZA ER.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — XTAMPZA ER (SUPPL)
FDAmedium relevance
Entity match (xtampza er)
FDA document
View source
FDA AP — XTAMPZA ER (SUPPL)
FDAmedium relevance
Entity match (xtampza er)
FDA document
View source
Report on the State of Pharmaceutical Quality
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedmedium relevance
Mechanism alignment (IO )
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Collegium Pharma
XTAMPZA ER

Commercial impact

medium

The approval could lead to increased market share for Collegium Pharma, potentially affecting revenue dynamics in the opioid segment as competitors may need to adjust their strategies.

Regulatory impact

medium

This approval indicates a positive regulatory environment for opioid formulations, which may influence future submissions and approvals in this therapeutic area.

What to watch

Monitor for any upcoming marketing strategies or additional indications for XTAMPZA ER.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.